Search
Showing results for "Childhood interstitial lung disease "
Stratification of monitoring protocols based on the risk profile of the patient can help us in the future to better care for people with Cystic Fibrosis.
Clinical trials for the treatment of cystic fibrosis (CF) lung disease are important to test and optimise new therapeutic interventions.
Several lipid biomarkers of early cystic fibrosis lung disease were identified, which point toward potential disease monitoring and therapeutic approaches
Pulmonary inflammation in surveillance bronchoalveolar lavage has a cumulative effect on structural lung disease extent, more so than infection
Cross-sectional studies implicate neutrophilic inflammation and pulmonary infection as risk factors for early structural lung disease in infants and young...
Almost one in five children across four remote Kimberley communities has some form of chronic lung disease, according to a new study co-designed and conducted in partnership with Aboriginal communities.
Shannon Simpson BMedSci (hons), PhD Head, Strong Beginnings Research, Co-head Foundations of Lung Disease 08 6319 1631 Shannon.simpson@thekids.org.au
This study aimed to explore the links between infection and where early damage due to CF is found in young children with CF. The results showed that
Metabolomic Biomarkers Predictive of Early Structural Lung Disease in Cystic Fibrosis. ABSTRACT Neutrophilic airway inflammation plays a role in
Quantitative assessment of airway dimensions in youngchildren with cystic fibrosis lung disease using chestcomputed tomography Abstract Objective: To